Lutathera (lutetium Lu 177 dotatate) Patient Assistance Program
Don’t let the high cost of brand peptide receptor radionuclide therapy disrupt your neuroendocrine tumor treatment. We help eligible patients access Lutathera (lutetium Lu 177 dotatate IV infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Lutathera (lutetium Lu 177 dotatate) is FDA-approved for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs in adults. First-in-class peptide receptor radionuclide therapy (PRRT) — delivers targeted radiation to somatostatin receptor-expressing tumor cells. Four IV infusion cycles at 8-week intervals.
- Without assistance, Lutathera courses commonly run approximately $200,000+ per full 4-cycle treatment course.
- Through AffordMyPrescriptions, qualifying patients can access Lutathera for a flat $69.95 per month.
- Other NET therapies: somatostatin analogs (octreotide LAR — Sandostatin brand and generic; lanreotide — Somatuline Depot brand), everolimus (Afinitor brand and generic — pancreatic NET, non-functional NET), sunitinib (Sutent — pancreatic NET), Xermelo (telotristat — brand for carcinoid syndrome diarrhea, adjunct to SSA), chemotherapy (capecitabine + temozolomide), targeted therapies for select mutations. Related PRRT: Pluvicto (Lu-177 vipivotide tetraxetan for PSMA-positive prostate cancer). Comprehensive NET specialty center care.
What is Lutathera Prescription Assistance Program?
The Lutathera Patient Assistance Program helps eligible patients access this PRRT at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but involves detailed applications, oncology/nuclear medicine coordination, somatostatin receptor imaging documentation, and renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Lutathera PAP enrollment for a flat $69.95 per month — so you never face a gap in Lutathera NET therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Lutathera enrollment — so you never face a gap in your neuroendocrine tumor treatment.
Pharmacy Price Comparison
- Without assistance, Lutathera costs tens of thousands per infusion. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Everolimus generic (alt) | ~$5,000/mo | Alt oral targeted therapy |
| NET specialty center | ~$50,000/infusion | Save substantially |
| Cancer center nuclear med | ~$52,000/infusion | Save substantially |
| Hospital outpatient | ~$55,000/infusion | Save substantially |
| 340B-eligible institution | ~$45,000/infusion | Save substantially |
| Octreotide LAR (SSA alt) | ~$5,000/mo | Alt SSA foundation therapy |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Lutathera — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Lutathera Prescription Program?
The Lutathera Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. NET care requires a multidisciplinary NET specialty center — endocrinology, oncology, surgical, and nuclear medicine coordination. Somatostatin analogs (octreotide LAR, lanreotide) remain foundation therapy for many NET patients.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Lutathera assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Lutathera is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Lutathera:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still ~$50,000/infusion even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Lutathera assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Lutathera Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Lutathera:
Lutathera is a peptide receptor radionuclide therapy (PRRT) — combining a somatostatin receptor-binding peptide (dotatate) with the lutetium-177 radioisotope. It delivers targeted radiation to somatostatin receptor-expressing tumor cells while sparing normal tissue — a novel targeted radiotherapy paradigm.
How It Works:
Neuroendocrine tumors (NETs) arise from neuroendocrine cells of the GI tract, pancreas, lungs, and other organs. Many NETs express somatostatin receptors — a target for both imaging (Gallium-68 DOTATATE PET/CT) and therapy (somatostatin analogs, PRRT). Progressive metastatic NETs historically had limited treatment options. Lutathera combines dotatate (a somatostatin receptor-binding peptide) with lutetium-177 (a beta-emitting radioisotope). The peptide binds somatostatin receptors on tumor cells; the radioisotope delivers targeted radiation to receptor-expressing cells — precision radiotherapy that targets NET cells while sparing surrounding tissue. The NETTER-1 trial demonstrated improved progression-free survival and quality of life vs high-dose octreotide LAR. Related PRRT: Pluvicto uses Lu-177 vipivotide tetraxetan for PSMA-positive metastatic castration-resistant prostate cancer.
Form and Use:
Lutathera IV infusion. Four cycles at 8-week intervals (32 weeks total). Amino acid infusion co-administered for renal protection. Requires somatostatin receptor imaging (Gallium-68 DOTATATE PET/CT or equivalent) to confirm target expression. A nuclear medicine facility with PRRT capability is required. Radiation safety precautions post-infusion.
Generic Availability:
No generic Lutathera. Other NET therapies: somatostatin analogs (octreotide LAR — Sandostatin brand and generic; lanreotide — Somatuline Depot brand — foundation therapy for many NET patients; SC or IM every 28 days), everolimus (Afinitor brand and generic — pancreatic NET, non-functional GI NET, lung NET), sunitinib (Sutent — pancreatic NET), Xermelo (telotristat — brand oral for carcinoid syndrome diarrhea inadequately controlled on SSA), chemotherapy (capecitabine + temozolomide for pancreatic NET; other regimens), targeted therapies for select mutations. Related PRRT: Pluvicto (Lu-177 vipivotide tetraxetan for prostate cancer). Comprehensive NET specialty center care is recommended. NET Research Foundation and Carcinoid Cancer Foundation.
Warnings:
Bone marrow suppression (myelosuppression — anemia, thrombocytopenia, lymphopenia, neutropenia — monitor CBC), secondary myelodysplastic syndrome and leukemia (delayed — rare but serious, monitor long-term), renal toxicity (concomitant amino acid infusion for renal protection; monitor renal function), hepatotoxicity, neuroendocrine hormonal crisis (initial treatment can trigger hormone release — pre-treat and monitor), infertility (radiation gonadal effects), embryo-fetal toxicity (contraindicated in pregnancy). Other: nausea, vomiting, decreased appetite, fatigue, abdominal pain. Radiation safety precautions for patient and caregivers post-infusion. Multidisciplinary NET specialty center care is essential.
FAQ (Frequently Asked Questions)
How much does Lutathera cost without insurance?
$50,000+ per infusion at cancer centers. A full 4-cycle course totals ~$200,000+. Somatostatin analog foundation therapy (octreotide LAR, lanreotide) is $5,000/month brand. Patient Assistance Programs are essential for the uninsured.
How is Lutathera different from somatostatin analogs?
Both target somatostatin receptors on NET cells. Octreotide LAR (Sandostatin) and lanreotide (Somatuline Depot) are somatostatin analogs — binding receptors for symptomatic and some antitumor benefit via signaling. Lutathera adds a lutetium-177 radioisotope to the somatostatin peptide — delivering targeted radiation to receptor-expressing cells. Complementary mechanisms — somatostatin analog therapy is often continued alongside/after Lutathera.
How does PRRT differ from external beam radiation?
External beam radiation delivers radiation from outside the body to a targeted region — risking adjacent normal tissue. Peptide receptor radionuclide therapy (PRRT) delivers a radioisotope selectively to receptor-expressing tumor cells throughout the body — targeted systemic radiotherapy, a precision advantage for metastatic disease. It requires target receptor expression confirmed by imaging.
Do I need imaging before Lutathera?
Yes — somatostatin receptor imaging (Gallium-68 DOTATATE PET/CT or equivalent) is required to confirm somatostatin receptor expression before Lutathera. Not all NETs express somatostatin receptors sufficiently for PRRT. Imaging determines eligibility.
What are Lutathera side effects?
Bone marrow suppression (monitor CBC), secondary MDS/leukemia (delayed — rare but serious), renal toxicity (amino acid co-infusion for protection), hepatotoxicity, nausea/vomiting, decreased appetite, fatigue, abdominal pain, hormonal crisis (initial treatment — pre-treat and monitor). Radiation safety precautions for caregivers. Requires specialty center care.
Take Control of Your Medication Costs
Peptide receptor radionuclide therapy revolutionized NET treatment. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.